PMID- 26095133
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20231213
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 11
IP  - 9
DP  - 2015
TI  - Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F 
      agonists and CGRP antagonists.
PG  - 1409-18
LID - 10.1517/17425255.2015.1055244 [doi]
AB  - INTRODUCTION: Dose-response curves for efficacy and tolerability are the 
      important determinants for the choice of doses of acute migraine drugs. AREAS 
      COVERED: Dose-response curves for the efficacy of seven triptans (5-HT1B/1D 
      receptor agonists), a 5-HT1F receptor agonist (lasmiditan) and four oral 
      calcitonin-gene related peptide receptor antagonists (telcagepant, MK-3207, BI 
      44370 TA and BMS-927711) in placebo-controlled trials were reviewed. In addition, 
      dose-response curves for adverse events (AEs) were reviewed. EXPERT OPINION: For 
      most triptans, the dose-response curve for efficacy is flat, whereas AEs often 
      increase with increasing doses. The two other groups of drugs also have flat 
      dose-response curves for efficacy. Overall, the triptans still have the most 
      favorable efficacy-tolerability profile. Current acute antimigraine drugs do not 
      fulfill the expectations of the patients, and thus, there are many unmet needs. 
      Although upcoming drugs may not be superior to triptans, migraine patients will 
      potentially benefit greatly from these, especially patients who are triptan 
      non-responders and patients with cardiovascular disease.
FAU - Hougaard, Anders
AU  - Hougaard A
AD  - a 1 University of Copenhagen, Glostrup Hospital, Danish Headache Centre, 
      Department of Neurology , Glostrup, Denmark.
FAU - Tfelt-Hansen, Peer
AU  - Tfelt-Hansen P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150626
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 0 (Tryptamines)
SB  - IM
MH  - Acute Disease
MH  - *Calcitonin Gene-Related Peptide Receptor Antagonists
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Migraine Disorders/*drug therapy/physiopathology
MH  - Receptors, Serotonin/drug effects
MH  - Serotonin Receptor Agonists/*administration & dosage/pharmacology
MH  - Tryptamines/*administration & dosage/pharmacology
MH  - Receptor, Serotonin, 5-HT1F
OTO - NOTNLM
OT  - acute treatment
OT  - adverse events
OT  - dose-response curve
OT  - efficacy
OT  - migraine.
EDAT- 2015/06/23 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/06/23 06:00
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 10.1517/17425255.2015.1055244 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2015;11(9):1409-18. doi: 
      10.1517/17425255.2015.1055244. Epub 2015 Jun 26.